Download Files:
Products Details
Product Description
– (R)-Clevidipine-13C,d3 is the deuterium and 13C labeled Clevidipine[1]. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[2].
Web ID
– HY-17436S3
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C20 13CH20D3Cl2NO6
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.;Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.;Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.;Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64.
Molecular Weight
– 460.33
SMILES
– O=C(C1=C(C)NC(C)=C(C(OCOC(CCC)=O)=O)[C@@H]1C2=CC=CC(Cl)=C2Cl)O[13C]([2H])([2H])[2H]
Clinical Information
– No Development Reported
Solubility
– 10 mM in DMSO
Target
– Calcium Channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
